Fifth Third Bancorp’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Fifth Third Bancorp’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-500	Closed	-$7K	–	2502
2014 Q3	$7K	Sell	500 -500	-50%	-$5.95K	﹤0.01%	2107
2014 Q2	$13K	Hold	1,000	–	–	﹤0.01%	1937
2014 Q1	$12K	Buy	+1,000	New	+$13.4K	﹤0.01%	1951

Other funds holding INFI

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Fifth Third Bancorp's INFI Position: Q4 2014 in Review

Fifth Third Bancorp sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2014, closing a stake of 500 shares — an estimated $7K sold.

Fifth Third Bancorp first reported a position in INFI in Q1 2014 and held it in 3 quarters. The position peaked at $13K in Q2 2014. 143 funds tracked by Wall St. Rank hold INFI as of Q4 2014.

Fifth Third Bancorp reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
Fifth Third Bancorp sold 500 Infinity Pharmaceuticals, Inc. shares in Q4 2014, an estimated $7K.
Fifth Third Bancorp first reported a position in Infinity Pharmaceuticals, Inc. in Q1 2014 and held it in 3 quarters.
Fifth Third Bancorp's Infinity Pharmaceuticals, Inc. position peaked at $13K in Q2 2014.
143 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2014.

Based on Fifth Third Bancorp's 13F filing for Q4 2014, filed 13 Feb 2015.